Clinical trials: Sirolimus, completed
Breast Cancer
Study of Combined Fulvestrant and Everolimus in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure
The primary objective of this study is to determine if estrogen receptor-targeted therapy with fulvestrant used in combination with Everolimus is an effective and safe therapy for women with hormone receptor positive metastatic…
- Trial name
- BRE-43 (NCT00570921)
- Testing
- Everolimus, Fulvestrant
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Mara Chambers
Carcinoma, Endometrioid, mTOR Protein
POEM STUDY: A Phase IIa Trial in Endometrial Carcinoma With Temsirolimus
Type of Application: Clinical trial of new indication. Experimental drug: The study dose of temsirolimus will be 25 mg administered intravenously, infused over a 30- to 60-minute period once weekly for 28 days (Total doses: 4…
- Trial name
- POEM (NCT02093598)
- Testing
- Temsirolimus
- Where
- 3 sites in Spain
- Volunteers
- 10 people
- Sponsor
- MedSIR
Kidney Transplantation, Kidney Disease
Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients
Alemtuzumab is a man-made antibody used to treat certain blood disorders. This study will evaluate treatment of kidney transplant recipients with alemtuzumab and other immune system suppressing medications with or without…
- Conditions
- Kidney Transplantation, Kidney Disease, Kidney Failure
- Trial name
- NCT00183248
- Testing
- Alemtuzumab, Mycophenolate mofetil, Sirolimus
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Miami
Coronary Artery Disease (CAD)
Coroflex ISAR 2000 Registry
Postmarket surveillance in terms of the safety and efficacy of Sirolimus-eluting Coroflex ISAR Stent for the treatment of "real world" patients with de-novo and restenotic lesions after stand-alone angioplasty in coronary arteries
- Trial name
- ISAR2000 (NCT02629575)
- Testing
- stenting with the Coroflex ISAR sirolimus-eluting stent
- Where
- 3 sites in Germany, Malaysia and 1 more
- Volunteers
- 2,877 people
- Sponsor
- B. Braun Melsungen AG
Kidney Transplantation
Envarsus® Once Daily With Everolimus in Elderly Kidney Transplant Recipients: Pharmacokinetic and Clinical Study
Prospective, single-arm, open-label, multicentre study with the principal aim to estimate tacrolimus pharmacokinetic parameters in elderly de-novo kidney transplant recipients of ECD (Extended Criteria Donor) kidney grafts…
- Trial name
- NCT02970630
- Testing
- Tacrolimus, Everolimus
- Where
- 6 sites in Italy
- Volunteers
- 28 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Diabetes Mellitus, Type 1
Minimal Islet Transplant at Diabetes Onset
This is a prospective phase 2, single-arm, mono-center pilot study. It has been designed to investigate whether giving the combination therapy consisting of minimal islet transplantation (1500 EIQ/Kg body weight), Thymoglobulin®…
- Trial name
- MITO (NCT02505893)
- Testing
- Human pancreatic islet, ATG, Pegylated G-CSF
- Where
- Italy
- Volunteers
- 6 people
- Sponsor
- Ospedale San Raffaele
Coronary Disease
EGO-COMBO Angiographic Extension Study
Evaluation of Endothelial ProGenitor Cell Capture Sirolimus-Eluting Stent by Optical Coherence Tomography: the COMBO Stent angiographic extension Study (EGO-COMBO angiographic extension Study)
- Trial name
- NCT01756807
- Testing
- The COMBO Stent
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Prof. Stephen Lee
Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
The main purpose of this first study combining an investigational dual mTOR inhibitor, CC-223, with other agents (erlotinib or the investigational agent, oral azacitidine) is to establish a maximum tolerated dose level for each…
- Trial name
- NCT01545947
- Testing
- CC-223, erlotinib, CC-223, oral azacitidine
- Where
- 9 sites in United States, Spain
- Volunteers
- 76 people
- Sponsor
- Celgene
Kidney Diseases
Comparison of Sirolimus to Tacrolimus for Long Term Therapy in Kidney Transplant With no Steroids
Kidney transplant patients will be treated with Thymoglobulin (5 days), tacrolimus (Prograf), and mycophenolate mofetil (Cellcept) from the time of transplant.
- Trial name
- NCT00170053
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 177 people
- Sponsor
- Mayo Clinic
Carcinoma, Renal Cell, Lymphoma, Mantle-Cell
INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Temsirolimus
The principal objective of the study is to evaluate the efficacy and safety of temsirolimus use in patients with Renal Cell Carcinoma and Mantle Cell Lymphoma.
- Trial name
- NCT01367457
- Testing
- Temsirolimus (Non-Interventional Study)
- Where
- 16 sites in Spain
- Volunteers
- 243 people
- Sponsor
- Pfizer
Coronary Artery Disease
The Study to Assess AMI Treated With Balloon Angioplasty.
The main objective of this study is to assess the effectiveness and safety of the CYPHER™ (CYPHER SELECT™) (Sirolimus-eluting) stent in reducing the occurrence of a composite endpoint of target vessel failure (TVF) in subjects…
- Trial name
- TYPHOON (NCT00232830)
- Testing
- drug-eluting stent, bare-metal stent
- Where
- 2 sites in France, Germany
- Volunteers
- 715 people
- Sponsor
- Cordis US Corp.
Type 1 Diabetes Mellitus, Hypoglycemia
MGA031, Sirolimus and Tacrolimus in Islet Transplantation
This clinical trial is designed to extend the observations made in our pilot clinical trial (IND 8971, Study #1) on the safety and efficacy of immunotherapy with the anti-CD3 monoclonal antibody hOKT3γ1 (Ala-Ala), (currently…
- Trial name
- NCT00265473
- Testing
- Allogeneic Islets of Langerhans
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Minnesota
Polycystic Kidney Diseases
Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
This study is a prospective, randomized, open-label, pilot clinical trial designed to compare the effects of an agent that has antiproliferative (1,2), antiangiogenesis (3),and tumor-progression blocking capabilities (4), namely…
- Trial name
- NCT00286156
- Testing
- Rapamune
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The Cleveland Clinic
Acute Leukemia, Myelodysplastic Syndromes
PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation
This is a single-arm, phase I/II, study of PTCy/sirolimus plus VIC-1911 to prevent GVHD and relapse after Allogeneic Hematopoietic Cell Transplantation (alloHCT).
- Conditions
- Acute Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Lymphoma
- Trial name
- NCT05120570
- Testing
- VIC- 1911
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Breast Cancer
Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00930930
- Testing
- cisplatin, everolimus, paclitaxel
- Where
- 8 sites in United States
- Volunteers
- 145 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Tuberous Sclerosis, Angiofibroma
Long-term Trial of Topical Sirolimus to Angiofibroma in Patient With Tuberous Sclerosis Complex
The purpose of this trial is to evaluate the safety and efficacy of long-term treatment with NPC-12G gel (0.2% sirolimus gel) to angiofibroma and other skin lesions in patients with tuberous sclerosis complex in the open-label…
- Conditions
- Tuberous Sclerosis, Angiofibroma, Hypomelanotic Macule, Plaque
- Trial name
- NCT02634931
- Testing
- NPC-12G gel
- Where
- Japan
- Volunteers
- 94 people
- Sponsor
- Nobelpharma
Bladder Cancer, Metastatic Transitional Cell Carcinoma
Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium
The purpose of this study is to learn what effects, good and/or bad, Everolimus has on advanced urothelial cancer. The goal of this clinical research study is to learn if the study drug Everolimus can shrink or slow the growth of…
- Trial name
- NCT00805129
- Testing
- Everolimus
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma and Plasma Cell Neoplasm
Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma
RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer.
- Trial name
- NCT00618345
- Testing
- everolimus, DNA analysis, protein analysis
- Volunteers
- 35 people
- Sponsor
- Mayo Clinic
HIV, Kidney Transplant
Impact of Everolimus on HIV Persistence Post Kidney or Liver Transplant
Zortress (everolimus), the 40-O-(2-hydroxyethyl)-derivative of rapamycin, is an mTOR inhibitor approved for rejection prophylaxis in kidney transplant recipients.
- Conditions
- HIV, Kidney Transplant, Liver Transplant
- Trial name
- HIVTR-EVE (NCT02429869)
- Testing
- everolimus
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, San Francisco
Advanced Cancer
Temsirolimus In Phase 0
The goal of this clinical research trial is to study the effects of the FDA-approved drug, temsirolimus, using a new type of clinical study design called a "Phase 0." This type of study may be able to predict if a drug can affect…
- Trial name
- NCT01417065
- Testing
- Temsirolimus
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.